Preclinical Models of Non-alcoholic Steatohepatitis Leading to Hepatocellular Carcinoma

Overview

Journal Adv Biol Regul

Publisher Elsevier

Specialties Biochemistry
Molecular Biology

Date 2023 Jan 27

PMID 36706611

Authors

Christopher D Green

Sarah Spiegel

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer related deaths worldwide and its incidence is increasing due to endemic obesity and the growing burden of non-alcoholic steatohepatitis (NASH) associated liver cancer. Although much is known about the clinical and histological pathology of NASH-driven HCC in humans, its etiology remains unclear and there is a lack of reliable biomarkers and limited effective therapies. Progress has been hampered by the scarcity of standardized animal models that recapitulate the gradual progression of NASH towards HCC observed in humans. Here we review existing mouse models and their suitability for studying NASH-driven HCC with special emphasis on a preclinical model that we recently developed that faithfully mimics all the clinical endpoints of progression of the human disease. Moreover, it is highly translatable, allows the use of gene-targeted mice, and is suitable for gaining knowledge of how NASH progresses to HCC and development of new targets for treatment.

References

Teufel A, Itzel T, Erhart W, Brosch M, Wang X, Kim Y . Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology. 2016; 151(3):513-525.e0. DOI: 10.1053/j.gastro.2016.05.051. View

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

Mollerhoj M, Veidal S, Thrane K, Oro D, Overgaard A, Salinas C . Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. Clin Transl Sci. 2022; 15(5):1167-1186. PMC: 9099137. DOI: 10.1111/cts.13235. View

Tsuchida T, Lee Y, Fujiwara N, Ybanez M, Allen B, Martins S . A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol. 2018; 69(2):385-395. PMC: 6054570. DOI: 10.1016/j.jhep.2018.03.011. View

Green C, Weigel C, Brown R, Bedossa P, Dozmorov M, Sanyal A . A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. FASEB J. 2022; 36(7):e22372. PMC: 9207938. DOI: 10.1096/fj.202200346R. View

Estes C, Anstee Q, Arias-Loste M, Bantel H, Bellentani S, Caballeria J . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018; 69(4):896-904. DOI: 10.1016/j.jhep.2018.05.036. View

Asgharpour A, Sanyal A . Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. Methods Mol Biol. 2022; 2455:19-30. DOI: 10.1007/978-1-0716-2128-8_2. View

Diehl A, Day C . Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. N Engl J Med. 2017; 377(21):2063-2072. DOI: 10.1056/NEJMra1503519. View

Clapper J, Hendricks M, Gu G, Wittmer C, Dolman C, Herich J . Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol. 2013; 305(7):G483-95. DOI: 10.1152/ajpgi.00079.2013. View

10.

Shalapour S, Lin X, Bastian I, Brain J, Burt A, Aksenov A . Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017; 551(7680):340-345. PMC: 5884449. DOI: 10.1038/nature24302. View

11.

Jensen T, Abdelmalek M, Sullivan S, Nadeau K, Green M, Roncal C . Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018; 68(5):1063-1075. PMC: 5893377. DOI: 10.1016/j.jhep.2018.01.019. View

12.

Huang D, Singal A, Kono Y, Tan D, El-Serag H, Loomba R . Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022; 34(7):969-977.e2. PMC: 9762323. DOI: 10.1016/j.cmet.2022.05.003. View

13.

Anstee Q, Reeves H, Kotsiliti E, Govaere O, Heikenwalder M . From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019; 16(7):411-428. DOI: 10.1038/s41575-019-0145-7. View

14.

Ward Z, Bleich S, Cradock A, Barrett J, Giles C, Flax C . Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019; 381(25):2440-2450. DOI: 10.1056/NEJMsa1909301. View

15.

Ioannou G . The Role of Cholesterol in the Pathogenesis of NASH. Trends Endocrinol Metab. 2015; 27(2):84-95. DOI: 10.1016/j.tem.2015.11.008. View

16.

Febbraio M, Reibe S, Shalapour S, Ooi G, Watt M, Karin M . Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?. Cell Metab. 2018; 29(1):18-26. PMC: 6326872. DOI: 10.1016/j.cmet.2018.10.012. View

17.

Nikolova-Karakashian M . Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide. Adv Biol Regul. 2018; 70:40-50. DOI: 10.1016/j.jbior.2018.11.004. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Cazanave S, Podtelezhnikov A, Jensen K, Seneshaw M, Kumar D, Min H . The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. Sci Rep. 2017; 7(1):17193. PMC: 5722878. DOI: 10.1038/s41598-017-17370-6. View

20.

Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J . p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells. Cancer Cell. 2016; 29(6):935-948. PMC: 4907799. DOI: 10.1016/j.ccell.2016.04.006. View